Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared on X:
“We celebrate our Autumn EORTC Lung Cancer Group Meeting!
Academic trials are increasingly challenging but essential to answer questions that shape patient care. Great future ideas and fruitful discussions!
You’re welcome to Join our group!”
You can also read: AMAZE-lung Trial: Triple Targeting With Amivantamab, Lazertinib and Bevacizumab in EGFR-Mutant NSCLC
